York-based Abingdon Health welcomes new data on its antibody tests

The sample population included a sub-set of 65 patients that had previously been infected with Covid-19 and 128 that had no previous infection.

The York-based firm's AbC-19TM rapid antibody test was effective in demonstrating the immune response of patients to the first dose of the Pfizer-BioNTech COVID-19 vaccine.

The study highlighted a differential immune response of two cohorts of patients: those previously infected with COVID-19 and those not infected.

Patients previously infected with Covid-19 showed a stronger immune response to the first dose of the Pfizer-BioNTech Covid-19 vaccine.

Abingdon Health said the initial data from the study being performed at the University of Birmingham supports the rationale that vaccination programmes could benefit from determining an individual's antibody status not only after vaccination but also prior to vaccination.

The firm added that should these results continue to be seen in further studies, and with other vaccines, this demonstrates that the A b C-19 TM antibody test could potentially assist in patient stratification and resource management in overburdened international healthcare settings.

---

Support The Yorkshire Post and become a subscriber today.

Your subscription will help us to continue to bring quality news to the people of Yorkshire. In return, you'll see fewer ads on site, get free access to our app and receive exclusive members-only offers.

So, please - if you can - pay for our work. Just £5 per month is the starting point. If you think that which we are trying to achieve is worth more, you can pay us what you think we are worth. By doing so, you will be investing in something that is becoming increasingly rare. Independent journalism that cares less about right and left and more about right and wrong. Journalism you can trust.

Thank you

James Mitchinson